Shares of biotechnology company MannKind (NASDAQ:MNKD) are taking a hit – down nearly 25% as of this writing. The reason?
What do you do when a company has “more debt than assets?” Maxim’s Jason Kolbert just lost patience with MNKD.
Chief scientist Shaw looks for unusual sources of return in MNKD and VRX.
MannKind Corporation (NASDAQ:MNKD), a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products for diabetes, today announced the appointment of …
As MannKind spends precious cash, it moves closer to the next capital raise (a.k.
One of the world’s top fund managers is backing volatile healthcare stocks VRX and MNKD.
H.C.
Jason Kolbert recently downgraded MNKD on cash flow concerns; after this Q3 print, looks like he was right.
Both TRXC and MNKD offer potentially big rewards, but at what cost?
MannKind’s capital raise is not enough, says Jason Kolbert.